|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM228382521 |
| 003 |
DE-627 |
| 005 |
20231224075802.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2013 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2013.05.008
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0761.xml
|
| 035 |
|
|
|a (DE-627)NLM228382521
|
| 035 |
|
|
|a (NLM)23770627
|
| 035 |
|
|
|a (PII)S1521-6616(13)00128-9
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Sethu, Swaminathan
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Immunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFNβ interact with the endogenous cytokine and activate complement
|
| 264 |
|
1 |
|c 2013
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 17.09.2013
|
| 500 |
|
|
|a Date Revised 21.10.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2013 The Authors. Published by Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a A subset of patients with relapsing-remitting multiple sclerosis (RRMS) on therapy with interferon beta (IFNβ) develop neutralising anti-drug antibodies (ADA) resulting in reduced, or loss of, therapeutic efficacy. The aims were to characterise the relative contributions of anti-IFNβ antibody isotypes to drug neutralising activity, ability of these antibodies to cross-react with endogenous IFNβ, to form immune complexes and activate complement. IFNβ-specific ADA were measured in plasma from RRMS patients treated with IFNβ1a (Rebif(®)). Neutralisation of endogenous and therapeutic IFNβ by ADA was determined by IFNβ bioassay. IFNβ-ADA profile was predominantly comprised of IgG1 and IgG4 antibody isotypes. The contribution of IgG4-ADA towards neutralising activity was found to be minimal. Neutralising IFNβ-ADA blocks endogenous IFNβ activity. ADA interaction with therapeutic IFNβ results in immune complex formation and complement activation. In summary, IgG1 and IgG4 IFNβ-ADA have the ability to neutralise therapeutic and endogenous protein and to activate complement
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Anti-drug antibody;
|
| 650 |
|
4 |
|a Complement
|
| 650 |
|
4 |
|a Immunogenicity;
|
| 650 |
|
4 |
|a Interferon beta;
|
| 650 |
|
4 |
|a Neutralising antibody;
|
| 650 |
|
4 |
|a Relapsing-remitting multiple sclerosis;
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
| 650 |
|
7 |
|a Immunologic Factors
|2 NLM
|
| 650 |
|
7 |
|a Interferon-beta
|2 NLM
|
| 650 |
|
7 |
|a 77238-31-4
|2 NLM
|
| 700 |
1 |
|
|a Govindappa, Karthik
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Quinn, Paul
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wadhwa, Meenu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Stebbings, Richard
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Boggild, Mike
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Naisbitt, Dean
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kimber, Ian
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pirmohamed, Munir
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Park, Kevin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sathish, Jean
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 148(2013), 2 vom: 15. Aug., Seite 177-85
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:148
|g year:2013
|g number:2
|g day:15
|g month:08
|g pages:177-85
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2013.05.008
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 148
|j 2013
|e 2
|b 15
|c 08
|h 177-85
|